Mississauga, ON -- (SBWIRE) -- 06/05/2013 -- AllPennyStocks.com Media, Inc. (http://www.AllPennyStocks.com/) announces its latest article titled “Sanuwave Treating Diabetic Foot Ulcer Patients in Phase 3 Clinical Trial.”
Companies mentioned in this article include Sanuwave Health, Inc. (OTCBB:SNWV), GlaxoSmithKline (NYSE:GSK), Merck & Co. (NYSE:MRK) and ALR Technologies, Inc. (OTCBB:ALRT).
Article Excerpt:
Diabetic foot ulcers, of DFUs, are one of the most common complications of diabetes mellitus. Further, diabetic foot ulcers can be extremely resilient when treated with today’s approved therapies, often leading to osteomyelitis, or inflammation of the bone or bone marrow, or even lower limb amputations. Worse yet, the diabetes population is growing faster than any other chronic disease on the planet. The diagnosis rate has accelerated by about 8 percent annually with about 22.3 million people living in the U.S. with type 1 or type 2 diabetes in 2012, according to a March report by the American Diabetes Association. That’s up from about 17.5 million five years earlier. Diabetics run a 15 percent to 25 percent chance of developing a DFU in their lifetime.
The cost of diabetes has skyrocketed because of the mushrooming population; totaling $245 billion in 2012, up 41 percent from $174 billion in 2007. With more than 100,000 diabetics having a foot amputated in 2007, the costs add-up substantially, considering costs associated with an amputation generally exceed $100,000. The average cost of just treating an infected DFU is around $20,000.
The full version of this article can be found at:
http://www.allpennystocks.com/aps_us/special-reports/362/sanuwave-treating-diabetic-foot-ulcer-patients-in-phase-3-clinical-trial.htm
About AllPennyStocks.com
AllPennyStocks.com is focused on the small-cap / penny stock market and has become a reputable name in the investment community. AllPennyStocks.com runs a Canadian and US site to provide investors in Canada as well as the United States with informative and unique content and information. AllPennyStocks.com runs daily technical penny stocks to watch, has a daily market write-up, provides company spotlights, runs unique most active pages strictly for penny stocks trading on the TSX, TSX Venture, NASDAQ and OTC BB, and much more information for the average investor.
AllPennyStocks.com also runs an email newsletter that aims to uncover stocks that are still under the radar of most investors. Criteria AllPennyStocks.com looks for includes strong revenues, a seasoned management, innovative business plans, among many others. AllPennyStocks.com also looks for companies that announce breaking news, recent 52-week highs/lows, technical breakouts, and other favorable corporate information.
Investors are encouraged to subscribe to the AllPennyStocks.com FREE e-mail newsletter and see what tens of thousands of other investors have already been receiving since 1999. Investors can receive their free newsletter subscription by clicking here: http://www.allpennystocks.com/aps_common/newsletter_free.asp.
Contact:
AllPennyStocks.com Media, Inc.
Peter Szafranski -- President
Phone: (905) 361-5680
E-Mail: peter@allpennystocks.com
Websites: http://www.allpennystocks.com / http://www.bullishinvestor.com
Note: AllPennyStocks.com has not received compensation for carrying the above-mentioned company; a full disclaimer can be viewed here: http://www.allpennystocks.com/aps_common/disclaimer.asp.